Wilson Disease — Copper Metabolism, Kayser-Fleischer Rings & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Wilson disease (hepatolenticular degeneration) is a rare autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene, which encodes a copper-transporting ATPase in hepatocytes. In Wilson disease, copper cannot be incorporated into ceruloplasmin or excreted into bile, leading to progressive copper accumulation in the liver, brain (particularly the basal ganglia and lenticular nuclei — the putamen and globus pallidus), cornea, and kidneys. The condition affects approximately 1 in 30,000 people worldwide, with a carrier frequency of 1 in 90. It typically presents between ages 5 and 35 years — unusually presenting after age 40 is uncommon. Wilson disease is a treatable and potentially curable condition if diagnosed early — making it one of the most important rare diseases to identify, as untreated Wilson disease is uniformly fatal, but treated Wilson disease patients can have a normal life expectancy.

Wilson disease is caused by biallelic (homozygous or compound heterozygous) loss-of-function mutations in the ATP7B gene on chromosome 13. Over 600 pathogenic variants have been identified; p.His1069Gln is the most common variant in Europeans (occurring on approximately 35-40% of disease alleles). ATP7B protein normally performs two essential functions in hepatocytes: incorporating copper into ceruloplasmin (which transports 95% of plasma copper) for secretion into the bloodstream; and excreting excess copper into bile for faecal elimination. When both copies of ATP7B are non-functional, copper accumulates first in the liver (causing hepatitis, cirrhosis), then spills into the bloodstream (as non-ceruloplasmin-bound copper — a toxic species) and deposits in the brain, cornea, and other organs. Risk factors are entirely genetic: autosomal recessive inheritance means both parents must carry a mutation (heterozygous carriers are unaffected); siblings of an affected individual have a 1 in 4 chance of being affected. Consanguinity increases risk.

Wilson disease presents with hepatic, neurological, or psychiatric manifestations — or a combination. Hepatic presentation (more common in children and young adults): ranges from asymptomatic liver enzyme elevation to acute hepatitis, acute liver failure (Wilsonian acute liver failure — with haemolytic anaemia, coagulopathy, and rapid progression to multi-organ failure, carrying very high mortality without transplant), or compensated or decompensated cirrhosis. Neurological presentation (typically in the 2nd-3rd decades): dysarthria (slurred speech — often the first sign); dysphagia; tremor (characteristically a 'wing-beating' or 'flapping' tremor of the outstretched arms — also called asterixis); dystonia; choreoathetosis; ataxia; Parkinsonism (rigidity, bradykinesia); and seizures. Psychiatric presentation: personality change, depression, psychosis, anxiety, and cognitive decline — often misdiagnosed as primary psychiatric illness for years. Ocular sign: Kayser-Fleischer (KF) rings — copper deposits at the periphery of the cornea (Descemet's membrane) appearing as a golden-brown or green ring visible on slit-lamp examination — present in over 95% of neurological WD and 50-60% of hepatic WD. Sunflower cataracts (copper deposits in the lens) — another ocular feature. Renal manifestations: Fanconi syndrome (proximal tubular dysfunction), haematuria, renal tubular acidosis.

Diagnosis requires a combination of clinical, biochemical, and genetic findings — no single test is pathognomonic. Leipzig score (2001 EASL criteria): a composite scoring system combining: Kayser-Fleischer rings (2 points); neuropsychiatric symptoms typical of WD (2 points); serum ceruloplasmin (less than 0.1 g/L = 2 points; 0.1-0.2 g/L = 1 point); Coombs-negative haemolytic anaemia (1 point); 24-hour urine copper greater than 100 microg/24h (1 point), or greater than 200 microg/24h (2 points) on penicillamine challenge; liver copper greater than 250 microg/g dry weight on biopsy (2 points); and characteristic mutations on genetic testing (4 points). Score 4+: WD very likely; 3: possible; less than 2: WD unlikely. Serum ceruloplasmin: low (below 0.2 g/L) in 85% of WD patients — but note: it can be falsely low in any cause of liver failure (a negative acute-phase response), and falsely normal in pregnancy or oestrogen use. 24-hour urine copper: elevated above 100 microg/24h in symptomatic WD. Liver biopsy with hepatic copper quantification: gold standard — greater than 250 microg/g dry weight is diagnostic. Liver histology also shows steatosis, glycogen-storing nuclei, focal necrosis, inflammation, and cirrhosis. MRI brain: T2 hyperintensities in the putamen, thalamus, and brainstem ('face of the giant panda' sign in the midbrain is characteristic). Genetic testing (ATP7B mutation analysis): confirms diagnosis and enables family screening.

Treatment is lifelong and must never be discontinued (even brief interruption can precipitate acute liver failure). Copper chelation: D-penicillamine (500-1500 mg/day in divided doses before meals) — historical first-line agent; chelates copper, dramatically increasing urinary copper excretion; approximately 50% of neurological patients worsen initially (due to mobilisation of brain copper) — limiting its use in neurological WD. Trientine (triethylene tetramine, 750-2000 mg/day) — preferred for neurological WD and patients intolerant of penicillamine; less neurological worsening (10-20%); also used in pregnancy. Zinc acetate (150 mg/day, three times daily before meals) — induces intestinal metallothionein, blocking dietary copper absorption; slower acting, no chelation; preferred for maintenance therapy and for presymptomatic patients (siblings detected by family screening); safe in pregnancy; mechanism is entirely different from chelators. Tetrathiomolybdate: experimental agent with rapid copper chelation and less neurological worsening than penicillamine — not widely licensed. Liver transplantation: indicated for Wilsonian acute liver failure (orthotopic liver transplantation corrects the underlying metabolic defect — the transplanted liver expresses normal ATP7B), decompensated cirrhosis not responding to chelation, and rarely for progressive neurological WD unresponsive to medical therapy. Transplantation corrects the hepatic defect and leads to neurological improvement in most patients. Dietary advice: avoid high-copper foods initially during treatment (shellfish, liver, nuts, chocolate, mushrooms, legumes); copper restriction alone is insufficient treatment. Monitoring: 24-hour urine copper, liver function tests, FBC, neurological assessment every 3-6 months.

Wilson disease causes progressive and sometimes irreversible hepatic, neurological, and psychiatric complications if untreated or if treatment is suboptimal or discontinued. Hepatic complications: Wilsonian acute liver failure — the most immediately life-threatening presentation — causes massive hepatocyte necrosis, Coombs-negative haemolytic anaemia, and acute renal failure; without liver transplantation, mortality is extremely high; chronic liver disease from years of copper accumulation causes portal hypertension (oesophageal varices, ascites, hepatic encephalopathy, splenomegaly), coagulopathy, and rarely hepatocellular carcinoma. Decompensated cirrhosis requires urgent orthotopic liver transplantation, which corrects the underlying metabolic defect. Neurological complications: progressive dysarthria, dysphagia, drooling, tremor (resting, postural, or intention), chorea, dystonia, parkinsonism, ataxia, and rarely seizures cause progressive disability; neurological WD may be fatal without treatment; neurological symptoms can paradoxically worsen acutely when D-penicillamine is started (copper mobilisation into the brain), which is why trientine is preferred for neurological presentations. Psychiatric complications: depression, anxiety, personality change, psychosis, and cognitive impairment significantly impair social and occupational function; psychiatric symptoms are frequently mistaken for primary mental illness, causing diagnostic delays of years. Ocular complications: Kayser-Fleischer rings (copper deposition in Descemet's membrane — visible on slit-lamp examination in virtually all neurological WD — do not impair vision) and sunflower cataracts (spoke-wheel pattern) are important diagnostic signs. Haemolytic anaemia from copper-mediated red cell damage occurs during acute presentations. Treatment complications: D-penicillamine causes neurological worsening in approximately 20–50% of patients when used for neurological WD; lupus-like syndrome, nephrotic syndrome, and thrombocytopaenia also occur.

Family screening is the most important preventive strategy: all first-degree relatives of diagnosed patients (siblings, children) should undergo ATP7B genetic testing and/or biochemical screening (serum ceruloplasmin, 24-hour urine copper, liver function tests). Presymptomatic treatment of affected siblings prevents all manifestations of Wilson disease — zinc acetate is typically used in asymptomatic individuals. Never stop treatment — acute deterioration including fatal acute liver failure has occurred after treatment discontinuation, even after years of stable therapy. Pregnancy: Wilson disease patients should continue treatment throughout pregnancy — zinc acetate is the preferred agent in pregnancy (penicillamine is teratogenic at high doses and trientine should be used at lower doses); monitor hepatic and neurological status closely. Water: if tap water is supplied through copper pipes, use a filter or boiled water (copper leaching can worsen copper load). Alcohol avoidance is strongly advised as alcohol compounds hepatic copper toxicity.

Wilson disease should be considered in any person aged 5-40 with: unexplained liver disease (elevated transaminases, hepatitis, cirrhosis, or acute liver failure); unexplained neurological symptoms (tremor, dysarthria, dystonia, gait abnormality) without alternative explanation; psychiatric symptoms with concurrent liver disease; and Kayser-Fleischer rings detected by an optician. Family members of anyone diagnosed with Wilson disease should be referred urgently for screening regardless of symptoms — presymptomatic patients can be treated to prevent any disease manifestation. Any established Wilson disease patient must seek immediate medical attention for: sudden jaundice, abdominal swelling, confusion, or worsening neurological symptoms — these suggest hepatic decompensation requiring urgent hospital assessment. Never stop taking Wilson disease medication without discussing with your hepatologist, even if you feel completely well.